HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
C9070 | Tafasitamab-cxix | Monjuvi | 2mg | Immunotherapy | Monoclonal Antibody | CD19 | 2020 | Jan 1, 2021 | Apr 1, 2021 | No Longer Used | ||
A9607 | Lutetium Lu 177 vipivotide tetraxetan | PLUVICTO | 1 millicurie | Radiopharmaceutical | Radiopharmaceutical | In Use | ||||||
NA | Aprepitant | Emend | 80 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
NA | Belumosudil | Rezurock | 200mg | Chemotherapy | Rho Kinase Inhibitor | ROCK1, ROCK2 | Yes | 2021 | In Use | |||
Capivasertib | Truqap | 160mg, 200mg | Chemotherapy | AKT Inhibitor | AKT 1/2/3 | Yes | 2023 | In Use | ||||
NA | Duvelisib | Copiktra | 15mg, 25mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2018 | In Use | |||
NA | Ponatinib | Iclusig | 45 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
NA | Acalabrutinib | Calquence | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Yes | 2017 | In Use | |||
J7510 | Prednisolone | Flo-Pred [DSC], Millipred, Millipred DP, Orapred ODT, Orapred [DSC], Pediapred, Prednisone Intensol, Veripred 20, Prednisolone Sodium Phosphate | 5 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1955 | Jan 1, 2000 | In Use | ||
NA | Avapritinib | Ayvakit | 25mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
Asciminib | Scemblix | 20mg,40mg | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Yes | 2021 | In Use | ||||
NA | Dabrafenib | Tafinlar | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BRAF | Yes | 2013 | Jan 1, 2004 | In Use | ||
NA | Anastrozole | Arimidex | 0.5 mg | Hormonal Therapy | Aromatase Inhibitor | Yes | 1995 | In Use | ||||
NA | Naldemedine | Symproic | 0.2mg | Ancillary Therapy | Opioid Antagonist | Yes | 2018 | In Use | ||||
NA | Nilutamide | Anadron, Nilandron | 150 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 1996 | In Use | ||||
NA | Chlorotrianisene | Anisene | 12 mg | Hormonal Therapy | Estrogen | Yes | 1992 | 1997 | In Use | |||
Lazertinib | Lazcluze | 80mg, 240mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2024 | In Use | ||||
NA | Thalidomide | Thalomid | 200 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
NA | Axitinib | Axitinib | 1 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
NA | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 25 mg | Ancillary Therapy | Chemoprotective | Antidote | Yes | 1952 | Jan 1, 1997 | In Use | ||
Q0167 | Dronabinol | Marinol | 2.5 mg | Ancillary Therapy | Antiemetic | CB1/CB2 | Yes | 1985 | Apr 1, 1998 | In Use | ||
NA | Ripretinib | Qinlock | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Yes | 2020 | In Use | |||
NA | Avapritinib | Ayvakit | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
S0190 | Mifepristone | Korlym, Mifeprex | 200 mg | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Yes | 2000 | Jan 1, 2001 | In Use | ||
Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.